Literature DB >> 31311465

Magnitude of Benefit of Combined Endovascular Thrombectomy and Intravenous Fibrinolysis in Large Vessel Occlusion Ischemic Stroke.

Dashiell F Young-Saver1, Jeffrey Gornbein2, Sidney Starkman3, Jeffrey L Saver1.   

Abstract

Background and Purpose- Quantifying the benefit magnitude of combined endovascular thrombectomy (EVT) and intravenous thrombolysis (IVT) versus nonreperfusion care in patients with acute ischemic stroke caused by large vessel occlusion would aid organization of regional stroke care systems. Methods- NINDS rt-PA Study (National Institute for Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator) and SWIFT PRIME trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment) patients were matched for prognosis (based on age and National Institutes of Health Stroke Scale) and definite/likely anterior circulation large vessel occlusion (based on National Institutes of Health Stroke Scale total score and item pattern), using optimal inverse variance matching, to determine comparative outcomes with nonreperfusion care alone, IVT alone, and IVT+EVT. Results- Matching yielded 240 patients, including 80 each treated with nonreperfusion care, IVT alone, and IVT+EVT, with, respectively, mean age 67.1, 67.1, and 66.9 and presenting deficit severity (National Institutes of Health Stroke Scale) mean 15.8, 15.9, and 15.9. Outcomes at 3 months for IVT+EVT versus nonreperfusion care included freedom from disability (modified Rankin Scale score, 0-1) 48.1% versus 21.3%, P=0.0004; functional independence (modified Rankin Scale score, 0-2) 62.9% versus 32.6, P=0.0001; and reduced disability over all 7 modified Rankin Scale levels, common odds ratio 3.34, P<0.0001. Outcomes for IVT alone versus nonreperfusion care included: freedom from disability 30.0% versus 21.3%, P=0.28 and reduced disability over all 7 modified Rankin Scale levels, common odds ratio 1.14, P=0.65. Compared with nonreperfusion care, the number needed to treat with EVT+IVT for 1 more patient to have reduced disability was 1.8. Conclusions- Matched patient analysis across randomized trials provides evidence that the strategy of combined IVT and mechanical thrombectomy is a highly beneficial treatment strategy for acute ischemic stroke caused by large vessel occlusion patients. A reasonable effect magnitude estimate is that, among every 100 patients treated, combined IVT+EVT reperfusion therapy, compared with no reperfusion therapy, reduces long-term disability in 57, including conferring functional independence upon 30.

Entities:  

Keywords:  fibrinolysis; freedom; prognosis; reperfusion; thrombectomy

Year:  2019        PMID: 31311465     DOI: 10.1161/STROKEAHA.118.023120

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  3 in total

Review 1.  Preserving stroke care during the COVID-19 pandemic: Potential issues and solutions.

Authors:  Enrique C Leira; Andrew N Russman; José Biller; Devin L Brown; Cheryl D Bushnell; Valeria Caso; Angel Chamorro; Claire J Creutzfeldt; Salvador Cruz-Flores; Mitchell S V Elkind; Pierre Fayad; Michael T Froehler; Larry B Goldstein; Nicole R Gonzales; Brian Kaskie; Pooja Khatri; Sarah Livesay; David S Liebeskind; Jennifer J Majersik; Asma M Moheet; Jose G Romano; Nerses Sanossian; Lauren H Sansing; Brian Silver; Alexis N Simpkins; Wade Smith; David L Tirschwell; David Z Wang; Dileep R Yavagal; Bradford B Worrall
Journal:  Neurology       Date:  2020-05-08       Impact factor: 9.910

2.  Effect of Conscious Sedation vs. General Anesthesia on Outcomes in Patients Undergoing Mechanical Thrombectomy for Acute Ischemic Stroke: A Prospective Randomized Clinical Trial.

Authors:  Chunguang Ren; Guangjun Xu; Yanchao Liu; Guoying Liu; Jinping Wang; Jian Gao
Journal:  Front Neurol       Date:  2020-03-24       Impact factor: 4.003

3.  Effect of Alteplase Use on Outcomes in Patients With Atrial Fibrillation: Analysis of the Initiation of Anticoagulation After Cardioembolic Stroke Study.

Authors:  Shadi Yaghi; Eva Mistry; Adam de Havenon; Christopher R Leon Guerrero; Amre Nouh; Ava L Liberman; James Giles; Angela Liu; Muhammad Nagy; Ashutosh Kaushal; Idrees Azher; Brian Mac Grory; Hiba Fakhri; Kiersten Brown Espaillat; Syed Daniyal Asad; Hemanth Pasupuleti; Heather Martin; Jose Tan; Manivannan Veerasamy; Charles Esenwa; Natalie Cheng; Khadean Moncrieffe; Iman Moeini-Naghani; Mithilesh Siddu; Erica Scher; Tushar Trivedi; Teddy Wu; Muhib Khan; Salah Keyrouz; Karen Furie; Nils Henninger
Journal:  J Am Heart Assoc       Date:  2021-07-29       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.